Managing diabetic foot ulcers: Economic consequences in the USA

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 1, 2003, Pages 25-32

  O'Brien, Judith ^a   Ward, Alex ^a   Salas, Maribel ^a  

^a CARO RESEARCH INSTITUTE   (United States)

Author keywords

Amputation; Diabetes; Economics; Foot ulcer; Pharmacoeconomics

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; EDUCATION PROGRAM; FOOT AMPUTATION; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICAL RESEARCH; OUTPATIENT CARE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; WOUND INFECTION;

EID: 0037319197     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.1.25     Document Type: Review

References (44)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States 2000. US Department of Health and Human Services, Centers for Disease Control and Prevention, GA, USA (2002).
2. American Diabetes Association. Economic consequences of diabetes mellitus in the United States in 1997. Diabetes Care 21, 296-309 (1998).
3. Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the US: 1990-1998. Diabetes Care 23, 1278-1283 (2000).
4. Harrington C, Zagari M, Corea J, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 23, 1333-1338 (2000).
5. Abbott CA, Vileikyte I, Williamson S, Carrington A, Boulton A. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 21, 1071-1975 (1998).
6. Muller SI, Grauw WJC, Van Gerwen WHEM, Bartelink ML, Van den Hoogen HJM, Rutten GHM. Foot ulceration and lower limb amputation in Type 2 diabetic patients in Dutch Primary Health Care. Diabetes Care 25, 570-574 (2002).
7. Wrobel JS, Mayfield JA, Reiber GE. Geographic variation of lower extremity major amputation in individuals with and without diabetes in the Medicare Population. Diabetes Care 24, 860-864 (2001).
8. American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care 22, 1354-1360 (1999).
9. Moss SE, Klein R, Klein BEK. The 14-year incidence of lower-extremity amputation in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 22, 951-959 (1999).
10. Brod M. Quality of life issues in patients with diabetes and lower extremity ulcers: patients and care givers. Quality Life Res. 7, 365-372 (1998).
11. Reiber GE, Vileikyte L, Boyko EJ et al. Causal pathway for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 22, 157-162 (1999).
12. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care 21(12), 2161-2177 (1998).
13. Boyko, EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle diabetic foot study. Diabetes Care 22, 1036-1042 (1999).
14. Manes CH, Papazoglou N, Sossidou E et al. Prevalence of diabetic neuropathy and foot ulceration: identification of potential risk factors - a population based study. Wounds 14(1), 11-15 (2002).
15. Bus SA, Yang QX, Wang JH, Smith MB, Wunderlich R, Cavanagh PR. Intrinsic muscle atrophy and toe deformity in the diabetic neuropathic foot. Diabetes Care 25, 1444-1450 (2002).
16. Peters EJG, Lavery LA. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care 24, 1442-1447 (2001).
17. American Diabetes Association. Preventive foot care in people with diabetes. Diabetes Care 21(12), 2178-2179 (1998).
18. Saaddline JB, Englegau M, Beckles GL, Gregg EW, Thompson TJ, Narayan KMV. A diabetes report card for the United States: quality of care in the 1990s. Ann. Intern. Med. 136, 565-574 (2002).
19. Reiber GE, Smith DG, Wallace C et al. Effect of therapeutic footwear on foot reulceration in patients with diabetes. A randomized controlled trial. JAMA 287(19), 2552-2558 (2002).
20. O'Brien JA, Jacobs LM, Pierce D. Clinical practice guidelines and the cost of care. A growing alliance. Int. J. Technol. Assess. Healthcare 16(4), 1077-1091 (2000).
21. Eyler N, Gilman J, Dehart L et al. Treating and preventing recurrent diabetic foot complications in the hospital: a need to improve preventive therapy? 62nd Scientific Session: American Diabetes Association, San Francisco, CA, USA, 1108-P, June 14-18 (2002).
22. Valsania, P, Gastwirth CM, Weitzman M, Allen BL. Academic detailing by volunteer podiatrists to improve foot care in the physician office. 62nd Scientific Session: American Diabetes Association, San Francisco, CA, USA, 2051-PO, June 14-18 (2002).
23. Pinzur MS, Kernan-Schroeder D, Emanuele NV, Emanuele M. Development of a nurse provided health system strategy for diabetic foot care. Foot Ankle Int. 22(9), 744-746 (2001).
24. Diabetes Guidelines Work Group for the Massachusetts Department of Public Health. Massachusetts Guidelines for Adult Diabetes Care. Massachusetts Health Promotion Clearing House, Boston, MA, USA (2001).
25. Mason J, O'Keeffe C, McIntosh A, Hutchinson A, Booth A, Young RJ. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus: prevention. Diabet. Med. 16, 801-812 (1999).
26. Wunderlich RP, Tredwell JL, Lavery LA. Reducing diabetes related lower extremity hospitalizations in a disease management model. 61st Scientific Session: American Diabetes Association, Philadelphia, PA, USA, 68-OR, June 22-26 (2001).
27. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (4) diabetic foot ulceration. Health Technol. Assess. 4(21), 1-237 (2000).
28. Armstrong DG, Nguyen HC, Lavery LA et al. Offloading the diabetic foot wound: a randomized clinical trial. 61st Scientific Session: American Diabetes Association, Philadelphia, PA, USA, 304-PP, June 22-26 (2001).
29. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. Diabetes Care 22 (5), 692-695 (1999).
30. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Risk factors for delayed healing of neuropathic diabetic foot ulcers. Arch. Dermatol. 136, 1531-1535 (2000).
31. Zimny S, Voigt A, Schatz H, Pfohl M. Prediction of wound radius reductions and healing times in neuropathic diabetic foot ulcers. 62nd Scientific Session: American Diabetes Association. San Francisco, CA USA, 1042-P, June 14-18 (2002).
32. Sheehan P, Caselli A, Pham H, Veves A. Change in foot ulcer area over a 4-week period can predict complete healing in a prospective clinical trial. 62nd Scientific Session: American Diabetes Association. San Francisco, CA, USA, 76-OR. June 14-18 (2002).
33. Beusterien K, Plante K, Nordin J et al. The cost-effectiveness of Graftskin vs. standard care for diabetic foot ulcers. 61st Scientific Session: American Diabetes Association, Philadelphia, PA, USA, 2082-PO, June 22-26 (2001).
34. Kantor J, Margolis D. Treatment options for diabetic neuropathic foot ulcers: a cost effectiveness analysis. Dermatol. Surg. 4, 347-351 (2001).
35. Ramsey SD, Newton K, Blough D et al. Incidence, outcomes and costs of foot ulcers in patients with diabetes. Diabetes Care 22, 382-387 (1999).
36. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed care population. PharmacoEconomics 6(3), 285-295 (1999).
37. O'Brien JA, Shomphe L, Kavanagh P, Raggio G, Caro JJ. Direct medical costs of complications resulting from Type 2 diabetes in the US. Diabetes Care 21(7), 1122-1128 (1998).
38. Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, Zagari M. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin. Ther. 20(1), 169-181 (1998).
39. O'Brien JA, Patrick AR, Caro JJ. Five year pattern of readmission for diabetic foot ulcers and lower extremity amputations. 62nd Scientific Session: American Diabetes Association. San Francisco, CA, USA, 1131-P, June 14-18 (2002).
40. O'Brien JA, Patrick AR, Caro JJ. Diabetic foot ulcers: the economic consequences of in-patient admissions over five years. 7th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Arlington, VA, USA, May 19-22 (2002).
41. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
42. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
43. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med 329, 977-986 (1993).
44. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 23, 390-404 (2000).